Stocks Health care UPC
NASDAQ · Health careUniverse Pharmaceuticals INC (UPC)
Universe Pharmaceuticals INC reported revenue of $17.9B in fiscal 2025, down 22.4% from a year earlier. It posted a net loss of $3.7B. In fiscal 2025 capital spending exceeded operating cash flow by $5.3B. At September 30, 2025 it held $33.6B in cash against $2.1B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on January 29, 2026.
What Universe Pharmaceuticals INC does
Universe Pharmaceuticals INC is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker UPC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $17.9B | -$3.7B | -$8.06 | -$5.3B |
| 2024 | $23B | -$8.7B | -$626.96 | -$9.7B |
| 2023 | $32.3B | -$6.6B | -$1,089.21 | $1.1B |
| 2022 | $40.1M | -$7.9M | -$1,309.11 | -$1.4M |
| 2021 | $48M | $11.3M | $1,944.65 | -$2.5M |
| 2021 | $30.7M | $7.6M | $1,523.31 | $6.1M |
Full financial statements: income, balance sheet and cash flow
Where UPC ranks in Health care
Dividends
It paid out $16M in cash dividends, 212% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2019 | n/a | $16M | 212% |
Latest SEC filings
What Universe Pharmaceuticals INC has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 3, 2026
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026
Insider trades
What the people running Universe Pharmaceuticals INC did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 7, 2026 | Lai GangChief Executive Officer, Director, 10% owner | Received as pay | 71,890 | - |
| May 7, 2026 | Lai GangChief Executive Officer, Director, 10% owner | Received as pay | 12,610 | - |
Who owns UPC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Origin Force Intelligence Limited13G, passive with 1 related filers | 18.3% | September 1, 2026 |
| Gang Lai13D, may seek influence with 1 related filers | 13.58% | May 21, 2026 |
| Orbis BioCapital Limited13G, passive with 1 related filers | 9.98% | September 1, 2026 |
| Horizon Ridge Limited13G, passive with 1 related filers | 9.97% | September 1, 2026 |
| Whitmore Limited13G, passive with 1 related filers | 9.97% | September 1, 2026 |
| Clever Way Global Limited13G, passive with 1 related filers | 9.96% | September 1, 2026 |
| Meridian Prosperous Limited13G, passive with 1 related filers | 9.96% | September 1, 2026 |
| Star Voyage International Limited13G, passive with 1 related filers | 9.94% | September 1, 2026 |
| August Luck Global Limited13G, passive with 1 related filers | 9.29% | September 1, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 84,500 shares in total, about $401.4K at the last price.
| Holder | Shares |
|---|---|
| Lai GangChief Executive Officer, Director, 10% owner | 84,500 |
Questions about UPC
What does Universe Pharmaceuticals INC do?
Universe Pharmaceuticals INC is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker UPC.
Is Universe Pharmaceuticals INC profitable?
No. In fiscal 2025 it reported a net loss of $3.7B on revenue of $17.9B.
How much revenue does Universe Pharmaceuticals INC make?
In fiscal 2025 Universe Pharmaceuticals INC reported revenue of $17.9B. That is 22.4% less than a year earlier.
When did Universe Pharmaceuticals INC last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on January 29, 2026. It covers the period to September 30, 2025. Its newest filing of any kind is the foreign issuer update (amended) from September 3, 2026.
Similar companies
Compare UPC with
Follow UPC
Get an email when Universe Pharmaceuticals INC files with the SEC: results, executive changes, material agreements and annual reports.
Follow UPC: get an email when it filesWhere the numbers come from
Financial figures are the values Universe Pharmaceuticals INC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.